EMEA anorexiants market is projected to register a CAGR of 2.7% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
EMEA Anorexiants Market, By Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End User (Hospitals, Specialty Clinics, Home Healthcare), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Netherlands, Spain, Russia, Switzerland, Saudi Arabia, South Africa, Turkey, Austria, UAE, Israel, Norway, Hungary, Lithuania, Kuwait, Ireland, Egypt, Poland, Rest of Europe & Middle East and Africa) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of EMEA anorexiants market are:
• Rise in geriatric population
• Increasing awareness about obesity
Market Players:
The key market players for EMEA anorexiants market are listed below:
• VIVUS Inc.
• Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.)
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Hikma Pharmaceuticals PLC
• Dr. Reddy’s Laboratories Ltd.
• Sandoz AG (A Business Division of Novartis AG)
• Mylan N.V.
• Bausch Health Companies Inc.
• Cipla Inc.
• Amphastar Pharmaceuticals, Inc.